{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:56:08Z","timestamp":1791896168999,"version":"4.3.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s11523-025-01154-4","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:26:29Z","timestamp":1749007589000},"page":"637-649","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase I Study of the Anti-CEACAM6 Antibody Tinurilimab (BAY 1834942) in Patients with Advanced Solid Tumors"],"prefix":"10.1007","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct03596372","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lillian L.","family":"Siu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf-Dietrich","family":"D\u00f6cke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reimo","family":"Tetzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Trautwein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Phelps","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Willuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang Qing","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Nogai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Cher","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"8","key":"1154_CR1","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/s41423-020-0488-6","volume":"17","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 2020;17(8):807\u201321. https:\/\/doi.org\/10.1038\/s41423-020-0488-6.","journal-title":"Cell Mol Immunol"},{"key":"1154_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108873","volume":"232","author":"H Akhbariyoon","year":"2021","unstructured":"Akhbariyoon H, Azizpour Y, Esfahani MF, et al. Immune checkpoint inhibition for the treatment of cancers: an update and critical review of ongoing clinical trials. Clin Immunol. 2021;232: 108873. https:\/\/doi.org\/10.1016\/j.clim.2021.108873.","journal-title":"Clin Immunol"},{"issue":"1","key":"1154_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. Br J Cancer. 2018;118(1):9\u201316. https:\/\/doi.org\/10.1038\/bjc.2017.434.","journal-title":"Br J Cancer"},{"key":"1154_CR4","doi-asserted-by":"publisher","first-page":"1170321","DOI":"10.3389\/fimmu.2023.1170321","volume":"14","author":"C Ursino","year":"2023","unstructured":"Ursino C, Mouric C, Gros L, Bonnefoy N, Faget J. Intrinsic features of the cancer cell as drivers of immune checkpoint blockade response and refractoriness. Front Immunol. 2023;14:1170321. https:\/\/doi.org\/10.3389\/fimmu.2023.1170321.","journal-title":"Front Immunol"},{"issue":"1","key":"1154_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-021-01056-8","volume":"14","author":"JA Marin-Acevedo","year":"2021","unstructured":"Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 2021;14(1):45. https:\/\/doi.org\/10.1186\/s13045-021-01056-8.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1154_CR6","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.1038\/s41467-020-17670-y","volume":"11","author":"C Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):3801. https:\/\/doi.org\/10.1038\/s41467-020-17670-y.","journal-title":"Nat Commun"},{"issue":"12","key":"1154_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1.","journal-title":"Exp Mol Med"},{"issue":"22","key":"1154_CR8","doi-asserted-by":"publisher","first-page":"4493","DOI":"10.1182\/blood-2012-05-429415","volume":"121","author":"M Witzens-Harig","year":"2013","unstructured":"Witzens-Harig M, Hose D, J\u00fcnger S, et al. Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 2013;121(22):4493\u2013503. https:\/\/doi.org\/10.1182\/blood-2012-05-429415.","journal-title":"Blood"},{"issue":"13","key":"1154_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2019-LB-075","volume":"79","author":"J Willuda","year":"2019","unstructured":"Willuda J, Boehm HH, Pinkert J, et al. Increased T cell-activation resulting from the combination of the anti-CEACAM6 function-blocking antibody BAY 1834942 with checkpoint inhibitors targeting either PD-1\/PD-L1 or TIM-3. Cancer Res. 2019;79(13): abstract LB-075. https:\/\/doi.org\/10.1158\/1538-7445.AM2019-LB-075.","journal-title":"Cancer Res"},{"issue":"1","key":"1154_CR10","doi-asserted-by":"publisher","first-page":"2008110","DOI":"10.1080\/2162402X.2021.2008110","volume":"11","author":"J Pinkert","year":"2022","unstructured":"Pinkert J, Boehm H-H, Trautwein M, et al. T cell-mediated elimination of cancer cells by blocking CEACAM6\u2013CEACAM1 interaction. Oncoimmunology. 2022;11(1):2008110. https:\/\/doi.org\/10.1080\/2162402X.2021.2008110.","journal-title":"Oncoimmunology."},{"issue":"3","key":"1154_CR11","doi-asserted-by":"publisher","first-page":"7686","DOI":"10.4238\/2014.September.26.6","volume":"13","author":"X Deng","year":"2014","unstructured":"Deng X, Liu P, Zhao Y, Wang Q. Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma. Genet Mol Res. 2014;13(3):7686\u201397. https:\/\/doi.org\/10.4238\/2014.September.26.6.","journal-title":"Genet Mol Res"},{"key":"1154_CR12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.cca.2012.09.003","volume":"415","author":"KS Kim","year":"2013","unstructured":"Kim KS, Kim JT, Lee SJ, et al. Overexpression and clinical significance of carcinoembryonic antigen-related cell adhesion molecule 6 in colorectal cancer. Clin Chim Acta. 2013;415:12\u20139. https:\/\/doi.org\/10.1016\/j.cca.2012.09.003.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"1154_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1038\/bjc.2012.422","volume":"107","author":"M Kobayashi","year":"2012","unstructured":"Kobayashi M, Miki Y, Ebina M, et al. Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma. Br J Cancer. 2012;107(10):1745\u201353. https:\/\/doi.org\/10.1038\/bjc.2012.422.","journal-title":"Br J Cancer"},{"issue":"3","key":"1154_CR14","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1097\/01.sla.0000154455.86404.e9","volume":"241","author":"MS Duxbury","year":"2005","unstructured":"Duxbury MS, Matros E, Clancy T, et al. CEACAM6 is a novel biomarker in pancreatic adenocarcinoma and PanIN lesions. Ann Surg. 2005;241(3):491\u20136. https:\/\/doi.org\/10.1097\/01.sla.0000154455.86404.e9.","journal-title":"Ann Surg"},{"issue":"19","key":"1154_CR15","doi-asserted-by":"publisher","first-page":"8809","DOI":"10.1158\/0008-5472.CAN-05-0420","volume":"65","author":"RD Blumenthal","year":"2005","unstructured":"Blumenthal RD, Hansen HJ, Goldenberg DM. Inhibition of adhesion, invasion, and metastasis by antibodies targeting CEACAM6 (NCA-90) and CEACAM5 (carcinoembryonic antigen). Cancer Res. 2005;65(19):8809\u201317. https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-0420.","journal-title":"Cancer Res"},{"issue":"14","key":"1154_CR16","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1200\/JCO.2012.45.7903","volume":"31","author":"Y Ji","year":"2013","unstructured":"Ji Y, Wang SJ. Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials. J Clin Oncol. 2013;31(14):1785\u201391. https:\/\/doi.org\/10.1200\/JCO.2012.45.7903.","journal-title":"J Clin Oncol"},{"key":"1154_CR17","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3389\/fimmu.2019.00464","volume":"10","author":"JC Anania","year":"2019","unstructured":"Anania JC, Chenoweth AM, Wines BD, Hogarth PM. The human Fc\u03b3RII (CD32) family of leukocyte FcR in health and disease. Front Immunol. 2019;10:464. https:\/\/doi.org\/10.3389\/fimmu.2019.00464.","journal-title":"Front Immunol"},{"issue":"13 Suppl","key":"1154_CR18","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2018-1771","volume":"78","author":"J Willuda","year":"2018","unstructured":"Willuda J, Trautwein M, Pinkert J, et al. BAY 1834942 is an immunotherapeutic antibody blocking the novel immune checkpoint regulator CEACAM6 (CD66c). Cancer Res. 2018;78(13 Suppl): abstract 1771. https:\/\/doi.org\/10.1158\/1538-7445.AM2018-1771.","journal-title":"Cancer Res"},{"key":"1154_CR19","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2019.02237","volume":"10","author":"SQ Nagelkerke","year":"2019","unstructured":"Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW. Genetic variation in low-to-medium-affinity Fc\u03b3 receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front Immunol. 2019;10:2237. https:\/\/doi.org\/10.3389\/fimmu.2019.02237.","journal-title":"Front Immunol"},{"key":"1154_CR20","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1479-5876-6-78","volume":"6","author":"KM Skubitz","year":"2008","unstructured":"Skubitz KM, Skubitz APN. Interdependency of CEACAM-1, -3, -6, and -8 induced human neutrophil adhesion to endothelial cells. J Transl Med. 2008;6:78. https:\/\/doi.org\/10.1186\/1479-5876-6-78.","journal-title":"J Transl Med"},{"issue":"2","key":"1154_CR21","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","volume":"7","author":"K Weiskopf","year":"2015","unstructured":"Weiskopf K, Weissman IL. Macrophages are critical effectors of antibody therapies for cancer. MAbs. 2015;7(2):303\u201310. https:\/\/doi.org\/10.1080\/19420862.2015.1011450.","journal-title":"MAbs"},{"issue":"12","key":"1154_CR22","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1182\/blood-2014-07-588376","volume":"125","author":"TRW Tipton","year":"2015","unstructured":"Tipton TRW, Roghanian A, Oldham RJ, et al. Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. Blood. 2015;125(12):1901\u20139. https:\/\/doi.org\/10.1182\/blood-2014-07-588376.","journal-title":"Blood"},{"issue":"3","key":"1154_CR23","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/19420862.2015.1022692","volume":"7","author":"M Kinder","year":"2015","unstructured":"Kinder M, Greenplate AR, Strohl WR, Jordan RE, Brezski RJ. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions. MAbs. 2015;7(3):494\u2013504. https:\/\/doi.org\/10.1080\/19420862.2015.1022692.","journal-title":"MAbs"},{"issue":"3","key":"1154_CR24","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.4049\/jimmunol.172.3.1882","volume":"172","author":"SP Hart","year":"2004","unstructured":"Hart SP, Alexander KM, Dransfield I. Immune complexes bind preferentially to Fc\u03b3RIIA (CD32) on apoptotic neutrophils, leading to augmented phagocytosis by macrophages and release of proinflammatory cytokines. J Immunol. 2004;172(3):1882\u20137. https:\/\/doi.org\/10.4049\/jimmunol.172.3.1882.","journal-title":"J Immunol"},{"issue":"4","key":"1154_CR25","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1046\/j.1365-2567.1997.00376.x","volume":"92","author":"MS Palermo","year":"2003","unstructured":"Palermo MS, Alves Rosa F, Fern\u00e1ndez Alonso G, Isturiz MA. Fc\u03b3 receptor-dependent clearance is enhanced following lipopolysaccharide in vivo treatment. Immunology. 2003;92(4):536\u201343. https:\/\/doi.org\/10.1046\/j.1365-2567.1997.00376.x.","journal-title":"Immunology"},{"issue":"3","key":"1154_CR26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1006\/clin.1998.4610","volume":"89","author":"MF Alves-Rosa","year":"1998","unstructured":"Alves-Rosa MF, Palermo MS, Isturiz MA. Enhancement of immune complex clearance by TNF-\u03b1 in a murine model. Clin Immunol Immunopathol. 1998;89(3):214\u201321. https:\/\/doi.org\/10.1006\/clin.1998.4610.","journal-title":"Clin Immunol Immunopathol"},{"issue":"3","key":"1154_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1158\/1535-7163.Mct-24-0444","volume":"24","author":"H Kogai","year":"2025","unstructured":"Kogai H, Tsukamoto S, Koga M, et al. Broad-spectrum efficacy of CEACAM6-targeted antibody-drug conjugate with BET protein degrader in colorectal, lung, and breast cancer mouse models. Mol Cancer Ther. 2025;24(3):392\u2013405. https:\/\/doi.org\/10.1158\/1535-7163.Mct-24-0444.","journal-title":"Mol Cancer Ther"},{"issue":"Suppl 2","key":"1154_CR28","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.annonc.2024.08.719","volume":"35","author":"MCH Ng","year":"2024","unstructured":"Ng MCH, Yong WP, Meric-Bernstam F, et al. A phase I dose escalation study of EBC-129, a first-in class, anti N-glycosylated CEACAM5 & CEACAM6 antibody-drug conjugate (ADC) in patients with solid tumors. Ann Oncol. 2024;35(Suppl 2):653. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.719.","journal-title":"Ann Oncol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-025-01154-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-025-01154-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T23:03:16Z","timestamp":1753916596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-025-01154-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1007\/s11523-025-01154-4","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"assertion":[{"value":"11 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by research funding from Bayer AG.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lillian L. Siu reports consulting\/advisory arrangements with Arvinas, AstraZeneca, Daiichi Sanyko, GlaxoSmithKline, LTZ Therapeutics, Marengo, Medicenna, Merck, Pfizer, Relay Therapeutics, Roche, Tubulis, and Voronoi; stock ownership in Agios (spouse); leadership position in Treadwell Therapeutics (spouse); and institution receives clinical trial support from AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, GlaxoSmithKline, Karyopharm, Merck, Novartis, Pfizer, and Roche\/Genentech. David S. Hong reports a consulting\/speaker\/advisory role with 280Bio (Yingli), AbbVie, Acuta, Adaptimmune, Affini-T, Alkermes, Alpha Insights, Amgen, Astellas, AUM Biosciences, Axiom, Baxter, Bayer, BeiGene, Boxer Capital, BridgeBio, CARSgen, CLCC, COG, COR2ED, EcoR1, EDDC, Erasca, Exelixis, Fate Therapeutics, F.\u00a0Hoffmann-La Roche, Genentech, Gennao Bio, Gilead, GLG Pharma, groupH, Guidepoint, HCW Precision Oncology, ImmunoGenesis, Incyte, InduPro, Inhibrx, Innovent, Janssen, Jounce Therapeutics, LianBio, Liberum Bio, MEDACorp, Medscape, Novartis, Northwestern, Numab Therapeutics, Oncologia Brasil, ORI Capital, Pfizer, Pharma Intelligence, Precision Oncology and Experimental Therapeutics, prIME Oncology, Projects in Knowledge, Quanta, Rain Therapeutics, Revolution Medicines, Ridgeline, Sanofi\/Genzyme, Seagen, Stanford, STCube, Takeda, Tavistock, TD Cowen, T-knife Therapeutics, Trieza Therapeutics, Turning Point Therapeutics, UNC, WebMD, and Ziopharm; research funding (all payments made to institution) from AbbVie, Adaptimmune, Adlai Nortye, Amgen, Astellas, AstraZeneca, Bayer, Biomea Fusion, Bristol Myers Squibb, Daiichi Sankyo, Deciphera, Eisai, Endeavor, Erasca, Fate Therapeutics, F.\u00a0Hoffmann-La Roche, Genentech, Genmab, ImmunoGenesis, Incyte, Infinity, Kyowa Kirin, Lilly, Merck, Mirati Therapeutics, National Cancer Institute Cancer Therapy Evaluation Program, Navier, Novartis, Numab Therapeutics, Pfizer, Pyramid Biosciences, Quanta, Revolution Medicine, Seagen, STCube, Takeda, TCR2 Therapeutics, Turning Point Therapeutics, and VM Oncology; travel\/accommodation\/expenses funding from American Association for Cancer Research, American Society of Clinical Oncology, Bayer, CLCC, Genmab, Northwestern, Society for Immunotherapy of Cancer, Telperian, and UNC; and other ownership interests in CrossBridge Bio (advisor), MolecularMatch (advisor), OncoResponse (founder, advisor), and Telperian (founder, advisor). Wolf-Dietrich D\u00f6cke is a stockholder in Bayer AG and an inventor on Bayer AG patent applications. Reimo Tetzner is an employee of and stockholder in Bayer AG. Mark Trautwein is an employee of and stockholder in Bayer AG and an inventor on Bayer AG patent applications. Charles Phelps is a stockholder in Amgen, Bayer AG, Janssen, Lilly, and Pfizer. Joerg Willuda is an employee of and stockholder in Bayer\u00a0AG and an inventor on Bayer AG patent applications. Xiang Qing Yu reports no conflicts of interest. Hendrik Nogai reports no conflicts of interest. Melissa Johnson reports a consulting\/advisory role (all payments made to institution) with AbbVie, Alentis Therapeutics, Amgen, Arcus Biosciences, ArriVent BioPharma, AstraZeneca, Biohaven, Boehringer Ingelheim, Bristol Myers Squibb, D3 Bio, Daiichi Sankyo, Fate Therapeutics, Genentech\/Roche, Gilead, GlaxoSmithKline, Gritstone Oncology, Hookipa Biotech, Immunocore, Janssen, Jazz, Lilly, Merck, Mirati Therapeutics, ModeX Therapeutics, Normunity, Novartis, Novocure, Pfizer, Pyramid Biosciences, Regeneron, Revolution Medicines, Sanofi-Aventis, Seagen, Synthekine, Takeda, and Zai Lab; and research funding (all payments made to institution) from AbbVie, Adaptimmune, Amgen, Arcus Biosciences, Array BioPharma, ArriVent BioPharma, Artios, AstraZeneca, Bayer, BeiGene, BerGenBio, BioAtla, Black Diamond Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Calithera Biosciences, Carisma Therapeutics, City of Hope National Medical Center, Conjupro Biotherapeutics, Corvus, Curis, CytomX, Daiichi Sankyo, Dracen, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics, Genentech\/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences, Immuneering Corporation, Immunitas Therapeutics, Immunocore, IMPACT Therapeutics, Incyte, Janssen, Kartos Therapeutics, Lilly, LockBody Therapeutics, Loxo Oncology, Memorial Sloan Kettering Cancer Center, Merck, Merus, Mirati Therapeutics, Mythic Therapeutics, NeoImmuneTech, Neovia Oncology, NextPoint Therapeutics, Novartis, Numab Therapeutics, Nuvalent, OncoC4, Palleon, Pfizer, PMV Pharma, Rain Therapeutics, RasCal Therapeutics, Regeneron, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals\/Birdie Biopharmaceuticals, Shattuck Labs, Silicon Therapeutics, Summit Therapeutics, Syndax, SystImmune, Taiho Oncology, Takeda, TCR2 Therapeutics, Tempest Therapeutics, Theras, Tizona Therapeutics, Tmunity Therapeutics, Turning Point Therapeutics, Vividion Therapeutics, Vyriad, and Y-mAbs Therapeutics. Boon Cher Goh reports clinical trial funding (all payments made to institution) from Bayer AG, and a leadership or fiduciary role (non-remunerated) on the Drug Advisory Committee, Ministry of Health, Singapore.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This study was approved by relevant independent ethics committees and institutional review boards at each study center and was compliant with the Declaration of Helsinki and Good Clinical Practice.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All patients provided written, informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"Availability of the data underlying this publication will be determined according to Bayer\u2019s commitment to the European Federation of Pharmaceutical Industries and Associations\/Pharmaceutical Research and Manufacturers of America \u201cPrinciples for responsible clinical trial data sharing.\u201d This pertains to scope, time point, and process of data access. As such, Bayer commits to sharing, upon request from qualified scientific and medical researchers, patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the USA and EU, as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after 1 January 2014. Interested researchers can use  to request access to anonymized patient-level data and supporting documents from clinical studies to conduct further research that can help advance medical science or improve patient care. Information on the Bayer criteria for listing studies and other relevant information is provided in the study sponsor\u2019s section of the portal. Data access will be granted to anonymized patient-level data, protocols, and clinical study reports after approval by an independent scientific review panel. Bayer is not involved in the decisions made by the independent review panel. Bayer will take all necessary measures to ensure that patient privacy is safeguarded.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors met the International Committee of Medical Journal Editors authorship criteria. Neither honoraria nor payments were made for authorship. Lillian L. Siu, Wolf-Dietrich D\u00f6cke, Reimo Tetzner, Mark Trautwein, Charles Phelps, Joerg Willuda, Xiang Qing Yu, and Hendrik Nogai were responsible for study conception and design. Lillian L. Siu, David S. Hong, Melissa Johnson, and Boon Cher Goh were responsible for data acquisition. All authors participated in data analysis or interpretation, drafted or critically revised the manuscript for intellectual content, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}